





















































































































































































to	NMD	 to	SLD	 to	CC	 Total	
from	NMD	 8	 4	 0	 12	
from	SLD	 4	 14	 1	 19	
from	CC	 0	 0	 1	 1	





	 to	NMD	 to	SLD	 to	CC	 Total	
from	NMD	 3	 3	 0	 6	
from	SLD	 6	 16	 2	 24	
from	CC	 0	 1	 0	 1	





























































































































































































































































































SLD-	to	HCC	 0.4%	 Annual	 probability	 of	 developing	 HCC	
from	fibrosis	stages	3	or	4:	0.004	(NAFLD	































-	 Mortality	 data	 for	 general	 population	
(life	tables	assuming	percentage	of	males	
and	initial	age	as	in	feasibility	study	[20])	
-	 Excess	 mortality	 due	 to	 diabetes	










Data	 for	 detected	 CC	 (CC+	 to	 death,	 see	
























trial	 [14],	 effect	 of	 glitazone	 (see	 Tables	
2.2a	and	2.2b)	
Supplementary	


















Annual	 probabilities	 for	 undetected	 SLD	
(SLD-	 to	 CC,	 see	 1a	 above)	 adjusted	 by	
RR=0.63	 (95%CI:	 0.06	 to	 6.45)	 from	 [14],	











as	 annual	 probability	 SLD-	 to	 HCC	 (no	
evidence	 indicating	 the	 effect	 of	 SLD	
detection	on	HCC	development)		















Probabilities	 of	 progression	 between	
Baveno	 stages	 (I	 and	 II	 –	 compensated	
cirrhosis,	 III	 and	 IV	 –	 decompensated	
cirrhosis)	 during	 the	 1st	 year	 after	



































-	 Mortality	 data	 for	 general	 population	
(life	tables	assuming	percentage	of	males	
and	initial	age	as	in	feasibility	study	[7]	
-	 Excess	 mortality	 due	 to	 diabetes	
(diabetes-related	 death	 rate	 of	 1.4%,	





















Probability	 of	 proceeding	 to	 death	
directly	 for	 patients	 with	 compensated	


























Age	 <	 70:	 5%,	
age	≥	70:	0%		
Probability	 of	 liver	 transplant	 for	







Probability	 of	 proceeding	 to	 death	
directly	for	patients	with	decompensated	





















	Calculation	 based	 on	 data	 from	 the	 US	
registries:	 the	 1-,	 2-,	 3-,	 4-	 and	 5-year	










Calculation	 based	 on	 the	 data	 published	
in	the	meta-analysis	of	9	studies,	Figure	2	
[29],	NASH	group:	598/717	(1-year	patient	



























































































































































































































































































































































































































































































































































































































































	 Autoimmune	liver	screen	 13	 Wright	et	al	(2006),	average	across	3	sites	
	














NMD Tests Fibroscan 1 37.31 37.31 [7, 56] 
  Primary care GP appointment 1 46.00 46.00 [7] 
  
	
Dietician appointment  1 80.00 80.00 [57] 
  Medication Glitazone   19.44 19.44 [57] 




182.75 182.75   
SLD Tests Liver function test 1 4.52 4.52 [58] 
  
	
Fibroscan 1 37.31 37.31 [7, 56] 
  
	
Hep B/C serology 1 30.00 30.00 [58] 
  
	
Ultrasound 1 49.35 49.35 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Consultant outpatient visit 2 393.02 393.02 [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medication‡  Glitazone  19.44 19.44 [57] 
Annual  cost per patient for SLD 
state  	






Tests OGD†† 1 276.93 416 [60] 
	
Fibroscan 1 37.31 37.31 [7, 56] 
	
LFT 1 4.52 4.52 [58] 
	
Hep B/C serology 1 30.00 30.00 [58] 
22	
	











Liver biopsy 1 546.02 546.02 [59] 
	
Ultrasound for HCC 2 98.70 98.70 [61] 
	
Alpha fetoprotein 2 9.04 9.04 [61] 
 Autoimmune liver screen 1 13.00 13.00 [58] 
Primary care GP appointment 1 46.00 46.00 [58] 
Secondary care Outpatient visits 2 393.02 393.02 [58] 
Other services Dietician appointment  1 80.00 80.00 [57] 
Medications‡   116.92 116.92 [57, 60, 62, 63] 
Annual  cost per patient for CC 
state  	
1651.46 1790.53   
DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGD for variceal bleed†† 4 1107.72 1664 
                                     
[60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
  Secondary care Emergency admission if ascites 1-3 1484.31 4452.93 [64],a 
  
	
Emergency admission of variceal 
bleed 
1-3 1317.10 3951.30 [60],a  
  
Emergency admission - 
encephalopathy 
1-3 2379.99 7139.97 [65],a 
  
	
Planned admission, ascites 0-1 0 1070.26 [44, 64] 
  
	
Planned admission, variceal bleed 0-1 0 901.32 [44],a 
  
	
Outpatient visits, ascites variceal 
bleeds or encephalopathy 
3-6 568.74 1095.90 [44],a 
  
TIPS stent – in 13% of patients with 
variceal bleed 
1 3930 3930 [55, 60] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡  NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 
Annual  cost per patient for DC 
state*  	
4221.30 9122.52   
HCC Secondary care Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission HCC resection 1 5362.01 5362.01 [44, 61, 67] 
  Hospital admission – follow-up 1 1535.32 1535.32 [44], a 
  
Day case chemoembolisation (TACE) 
or radiofrequency ablation (RFA) 
1 639.53 639.53 [44, 61, 67] 
  Day case follow-up 1 359.98 359.98 [44],a  
  
	
Outpatient visits 4-7 744.46 1271.62 [44]a 
  
	
Hospital admission - tumour 
recurrence (probability 17.1%) 
1 916.90 916.90 [47] 
  Medications Sorafenib   38879.17 38879.17 [61] 
Annual  cost per 





Transplant Secondary care first year cost based on Longworth et 1 89282.20 (Range [48, 49] 
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al, subtracting cost for 2nd year based 
on Ouwens et al 
56300.60,184574.29)† 




      
89282.20 (Range 





















NMD Tests Fibroscan (every3  years)  0.333 12.43 12.43 [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medication  Glitazone   19.44 19.44 [57, 62] 
Annual  cost for NMD 
state  	
157.87 157.87   
SLD Tests Liver function test 1 4.52 4.52 a 
  
	
Fibroscan 1 37.31 37.31 a, [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Consultant outpatient visits 1 175.72 175.72 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡ Glitazone  19.44 19.44 [57, 62] 
Annual  cost for SLD 
state  	
362.99 362.99   
CC Tests OGD†† 0.5 138.47 208.00 [60] 
  
	
Fibroscan 1 37.31 37.31 [69], a 
  
	
LFT 2 9.04 9.04 a 
  
	
Ultrasound for HCC 2 98.70 98.70 [61], a 
  
	
Alpha fetoprotein 2 9.04 9.04 
                                
[61] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Outpatient visits 2 351.44 351.44 a 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medication‡     116.92 116.92 [60, 70] 
Annual  cost for CC 
 	
886.92 956.45   
24	
	







DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGD for variceal bleed†† 4 1107.72 1664 [60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
 Secondary care Emergency admission for ascites 1-3 1484.31 4452.93 
[64], 
a 
  Emergency admission of variceal bleed 1-3 1317.10 3951.30 
a, 
[60] 















Oupatient visits, ascites or variceal bleeds 3-6 527.16 1054.32 
[44], 
a 
  TIPS stent – 13% of patients with variceal bleed 1 3930 3930 
[55, 
60] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡ NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 




HCC Secondary care Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission – follow-up 1 1535.32 1535.32 
[44], 
a 










Hospital admission - tumour recurrence 
(probability 17.1%) 
1 916.90 916.90 
[47], 
a 
  Medications  Sorafenib   38879.17 38879.17 [61] 
Annual  cost for HCC 
state** 	 	





Based on Longworth et al, probability 5% 
0.0
5 
































State Type Service Units Min cost Max cost Source 
NMD Tests Fibroscan 1 37.31 37.31 [57, 69] 
  LFT 2 9.04 9.04 [58] 
  Hep B/C serology 1 30.00 30.00 [58] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Ultrasound 1 49.35 49.35 [58] 
  Liver biopsy 1 546.02 546.02 [59] 
  Primary care GP appointment 1 46.00 46.00 [58] 
 Secondary care Consultant outpatient visit 2 393.02 393.02  [58] 
 Other services Dietician services  1 80.00 80.00 [57] 
  Medications     Glitazone   19.44 19.44 a, [57] 
Annual  cost for NMD 
state  	
1223.18 1223.18   
SLD Tests Liver function test 2 9.04 9.04 [58] 
  
	
Fibroscan 1 37.31 37.31 




Hep B/C serology 1 30.00 30.00 [58] 
  
	
Ultrasound 1 49.35 49.35 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Consultant outpatient visit 2 393.02 393.02 [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
 Medications‡  Glitazone  19.44 19.44 [57] 
Annual  cost for SLD 
state  	
1223.18 1223.18   
CC Tests OGD 1 276.93 416 [60] 
  
	
Fibroscan 1 37.31 37.31 [69] 
  
	
LFT 2 9.04 9.04 [58] 
  
	
Hep B/C serology 1 30.00 30.00 [58] 
  
	
Liver biopsy 1 546.02 546.02 [59] 
  
	
Ultrasound for HCC 2 98.70 98.70 [61] 
  
	
Alpha fetoprotein 2 9.04 9.04 [61] 
  Autoimmune liver screen 1 13.00 13.00 [58] 
26	
	
State Type Service Units Min cost Max cost Source 
  Primary care GP appointment 1 46.00 46.00 [58] 
  Secondary care Outpatient visits 2 393.02 393.02 a, [58] 
  Other services Dietician appointment  1 80.00 80.00 [57] 
  Medications‡   116.92 116.92 [60, 63] 
Annual  cost for CC 
state 	 	
1655.98 1795.05   
   2354.64 2493.71  
DC Tests OGD†† 1 276.93 416 [60] 
  Additional OGDs for variceal bleed†† 4 1107.72 1664 [60] 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184.00 184.00 a 
  Secondary care Emergency admission if ascites 1-3 1484.31 4452.93 a, [64] 
  
	
Emergency admission of variceal bleed 1-3 1317.10 3951.30 [60], a  
  
Emergency admission for 
encephalopathy 








0 1070.26 [44, 64] 
  
	




0 901.32 [44], a 
  
	




568.74 1095.90 [44], a 








NAFLD ascites  115.05 115.05 [64] 
  NAFLD variceal bleeding  20.09 20.09 [60] 
  NAFLD encephalopathy  3508.67 3508.67 [66] 
Annual  cost for DC 
state*  	
4221.30 9122.52   
HCC Secondary 
care 
Nurse telephone consultations 3 25.20 25.20 a 
  Hospital admission HCC resection 1 5362.01 5362.01 [44, 61, 67] 
 Hospital admission – follow-up 1 1535.32 1535.32 [44], a 
  
Day case chemoembolisation (TACE) or radiofrequency 
ablation (RFA) 
1 639.53 639.53 [44, 61, 67] 







744.46 1271.62 [44], a 
  
	
Hospital admission - tumour recurrence (probability 
17.1%) 




Sorafenib   38879.17 38879.17 [61] 
Annual  cost for HCC 
	 	




Transplant All services 
First year cost: based on Longworth et al and 






Annual   cost  for  
transplant state 


















State Type Service Units Min cost Max cost Source 
 Primary care GP visit (NAFLD)  46.00 46.00 a 
NMD Medications Glitazone (NAFLD)  19.44 19.44 a  
Annual  cost  for  NMD state 
 	
65.44 65.44   
SLD Tests Liver function test 2 9.04 9.04 a 
  
	
Fibroscan 1 37.31 37.31  [69] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care 
Consultant 
outpatient visits 
1 175.72 175.72 a 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
 Medications‡  Glitazone  19.44 19.44 [57] 
Annual  cost  for  SLD state  
 	
367.51 367.51   
CC Tests OGD†† 0.5 138.47 208 [60] 
  
	





2 98.70 98.70 [61] 
  
	
Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointment 1 46.00 46.00 a 
  Secondary care Outpatient visits 2 351.44 351.44 a 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
  Medications‡     116.92 116.92 [60, 63] 
Annual  cost  for  CC state 
 	
849.61 919.14   




4 1107.72 1664 [60] 
28	
	
State Type Service Units Min cost Max cost Source 
bleed†† 
  Ultrasound 2 98.70 98.70 [61] 
  Alpha fetoprotein 2 9.04 9.04 [61] 
  Primary care GP appointments 4 184 184 a 














1-3 2379.99 7139.97 [65], a 
  
	










ascites or variceal 
bleeds 
3-6 527.16 1054.32 a, [44] 
  
TIPS stent - in 
13% of patients 
with variceal 
bleed 
1 3930 3930 [60], [55] 
  Other services 
Dietician 
appointment  
1 80.00 80.00 [57] 
  NAFLD ascites  115.05 115.05 [64] 
 Medications‡  
NAFLD variceal 
bleeding 




 3508.67 3508.67 [66] 





Secondary care Nurse telephone 
consultations 








1 359.98 359.98  








1 916.90 916.90 [47], a 
29	
	
State Type Service Units Min cost Max cost Source 
Medications  Sorafenib   38879.17 38879.17 [61] 










Based on Longworth et al 
and Ouwens et al, refer to 

















































































































































































































































































































































































































































































































NMD	 Pioglitazone	 30	 1	 1.49	 840	 28	 19.44	
Subtotal	 	 	 	 	 	 	 19.44	
SLD	 Pioglitazone	 30	 1	 1.49	 840	 28	 19.44	
		 Acamprosate	 666	 3	 28.92	 111888	 56	 188.63	
Subtotal	
	 	 	 	
		 		 208.06	
CC	 Carvidilol	 12.5	 1	 1.54	 350	 28	 20.09	
		 Multivitamins	 2	 1	 11.93	 90	 45	 96.83	
Subtotal	











syndrome	 100	 1	 1.5	 2000	 20	 27.39	
		
Spironolactone	-	
ascites	 100	 2	 3.55	 2800	 14	 92.62	
		
Furosemide	-	
ascites	 40	 2	 0.86	 1120	 14	 22.44	
		
Rifaximin	-	
encephalopathy	 550	 2	 259.23	 56	 28	 3381.56	
		
Lactulose	-	
encephalopathy	 20	 3	 2.9	 500	 8.333333	 127.11	
	 NAFLD	ascites	 	 	 	 	 	 115.05	
	
NAFLD	variceal	
bleeding	 	 	 	 	 	 20.09	
	
NAFLD	
encephalopathy	 	 	 	 	 	 3508.67	
HCC	 Sorafenib	 400	 2	 2980.47	 22400	 28	 38879.17	
Subtotal	 		 		 		 		 		 		 38879.17	
Transplant	 Tacrolimus	 2	 2	 111.36	 100	 25	 1626.97	
		 Azathioprine	 100	 1	 3.54	 2800	 28	 46.18	
		 Prednisolone	 29.23	 1	 1.33	 140	 4.7896	 25.27	
Subtotal	first	year	 		 		 		
	 	
1698.42	















































































































































15549		 The	 lowest	 estimated	 cost,	
see	 Tables	 4.3,	 4.5,	 and	 4.6-
4.7	
512	 2138	
25452		 The	 highest	 estimated	 cost,	






19151	 Assumed	 4	 outpatient	 visits	
per	year,	see	Table	4.2		
513	 2143	






17909	 Assumed	 4	 outpatient	 visits	
per	year,	see	Table	4.3			
514	 2148	





4221	 The	 lowest	 estimate	 (see	
Table	3)	
600	 2507	






5525	 The	 lowest	 estimate	 (see	
Table	3)	
716	 2992	















The	 lowest	 and	 the	 highest	
































































HCC	utility,	0.65	 0.44	 Lower	95%CI	limit,	Table	2	 0.24	 2115	
0.86	 Upper	95%CI	limit,	Table	2		 0.24	 2163	
DC	utility,	0.66	 0.46	 Lower	95%CI	limit,	Table	2	 0.27	 1929	




0	 Arbitrary	assumption	 0.29	 1789	






0.06	 Lower	 limit	 of	 95%CI,	 see	
Appendix	2	
-766	 0.40	 -1895	






0.21	 Lower	 limit	 of	 95%CI,	 see	
section	Appendix	2	
-594	 0.32	 -1852	











multipliers	 based	 on	 expert	
panel	 responses	 (see	 Table	
2.3)	
600	 0.22	 2686	
2.0	 364	 0.26	 1373	
Mortality	from	CC-	
multiplier**,	1.4	
1.0	 488	 0.24	 2069	




1.0	 543	 0.24	 2282	




1.4	 513	 0.24	 2144	
1.5	 510	 0.24	 2133	
Fibrosis	progression	
rate	
0.06	 Lower	95%CI	limit	in	[79]	 857	 0.12	 7032	























18.5%	 470	 0.24	 1953	
CCI->DCIV,	0.8%	
	
0.4%	 525	 0.24	 2195	
1.5%	 489	 0.24	 2044	
CCII->DCIII,	17.1%	
	
13.8%	 518	 0.24	 2163	










































7.5%	 506	 0.24	 2115	
CCI	->death,		7.5%		
	
6.1%	 491	 0.24	 2072	
9.1%	 533	 0.24	 2207	
CCII->death,	6.6%	
	
3.9%	 509	 0.24	 2128	




22.3%	 413	 0.23	 1783	




16.2%	 474	 0.24	 2005	
25.2%	 543	 0.24	 2247	
CC1	to	CCIII,	3.2%	 2.3%	 515	 0.24	 2154	
4.4%	 507	 0.24	 2118	
DCIII	to	DCIV,	3.2%	 2.1%	 517	 0.24	 2158	









decrease	 by	 20	 percentage	
points	 (0%	 assumed	 if	
negative	percentage).			
408	 0.20	 2032	




0%	 557	 0.25	 2265	




0%	 619	 0.35	 1773	




0%	 613	 0.26	 2382	









0.7%	 The	minimal	value	in	[16]	 561	 0.24	 2313	






65	yrs	 Assumed	 cut-off	 for	 DC	 to	
transplant	 the	 same	 as	 for	
HCC	
512	 0.24	 2138	
70	yrs	 Assumed	 cut-off	 for	 HCC	 to	
transplant	the	same	as	for	DC	
512	 0.24	 2138	
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